IGF::OT::IGF: PRECLINICAL MEDICATIONS DISCOVERY AND ABUSE LIABILITY TESTING FOR NIDA. N01DA-17-8932.

该合同为评估啮齿类和灵长类动物药物依赖障碍的潜在药物治疗提供了支持。它还为新的街头毒品、药物或潜在药物在啮齿动物和灵长类动物中的滥用责任相关测试提供支持。主要的重点是为NIDA的成瘾治疗发现计划（ATDP）进行的测试。在较小程度上，该合同将产生滥用责任数据，用于根据国内法（管制物质法）和国际条约（单一公约和精神药物公约）作出有关药物附表的决定。由于NIDA与制药公司合作的机会、药物成瘾研究领域的进展以及ATDP顾问的建议等因素的影响，NIDA对该合同的测试需求将是动态的。

This contract provides support for evaluation of potential pharmacotherapies for drug dependence disorders in both rodents and primates. It also provides support for abuse liability-related testing of new street drugs, medications, or potential medications in rodents and primates. The primary emphasis is on testing conducted for NIDA's Addiction Treatment Discovery Program (ATDP). To a lesser extent, the contract will generate abuse liability data for use in decisions pertaining to scheduling of drugs under domestic laws (Controlled Substances Act) and international treaties (Single Convention and Psychotropic Convention). NIDA's testing needs for this contract will be dynamic, due to the influences of such factors as opportunities for NIDA/pharmaceutical company collaboration, advances in the field of drug addiction research, and advice from consultants to the ATDP.